Previous 10 | Next 10 |
2024-03-07 07:10:11 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid Solid Biosciences wins FDA orphan status for gene therapy (update) Solid Biosciences raises $109M through private placement Seeking Alpha...
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non-exclusive worldwide license and collaboration agreement with Armatus Bio for t...
2024-03-05 11:03:07 ET More on Regenxbio REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio Q4 2023 Earnings Preview Regenxbio spikes after trial win for gene therapy in Hu...
2024-02-15 15:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-30 17:31:21 ET Gainers: NKGen Biotech ( NKGN ) +37% . Powell Industries ( POWL ) +15% . Manhattan Associates ( MANH ) +4% . WAVE Life Sciences ( WVE ) +4% . Arbutus Biopharma Corporation ( ABUS ) +3% . Losers:...
2024-01-30 16:17:02 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid Solid Biosciences wins FDA orphan status for gene therapy (update) Read the full article on Seeking Alpha For further details see: So...
2024-01-25 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-16 23:01:41 ET Summary IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. ...
2024-01-16 08:34:00 ET More on Solid Biosciences Solid Biosciences raises $109M through private placement Solid Biosciences receives FDA Fast Track designation for Duchenne gene therapy candidate Seeking Alpha’s Quant Rating on Solid Biosciences Histor...
– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it ...
News, Short Squeeze, Breakout and More Instantly...
Solid Biosciences Inc. Company Name:
SLDB Stock Symbol:
NASDAQ Market:
Solid Biosciences Inc. Website:
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the Company has been added to the broad-market Russell 3000 ® Index as ...
2024-06-21 08:15:07 ET Piper Sandler analyst issues OVERWEIGHT recommendation for SLDB on June 21, 2024 06:49AM ET. The previous analyst recommendation was Overweight. SLDB was trading at $6.3 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...